Reagents and instruments for immunology, cell biology and molecular biology.
 
> Ruxolitinib [941678-49-5]

Ruxolitinib [941678-49-5]

Print Print
Please log in

Cat# 10-4511-25mg

Size : 25mg

Brand : Focus Biomolecules

Request more information

Ruxolitinib | JAK inhibitor

CAS:
941678-49-5
Catalog Number:
10-4511
Activity:
JAK inhibitor
Alternate Names:
INCB 018424
Chemical Name:
βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
Molecular Weight:
306.37
Molecular Formula:
C17H18N6
Solubility:
Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).
Physical Properties:
White solid
Purity:
99% by HPLC
NMR (Conforms)
Storage Temperature:
-20°
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Shipping Code:
RT

Available Options

Size : Quantity 
5 mg$65.00
25 mg$150.00
Request Quote / Bulk / Custom Size
Product Inquiry

Ruxolitinib (941678-49-5) is a potent and selective JAK1/2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1  Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4 Clinically useful cancer chemotherapeutic.

References/Citations:

1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636
2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109
3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med. 23 1072
4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget 8 34687

CAS:
941678-49-5
Catalog Number:
10-4511
Activity:
JAK inhibitor
Alternate Names:
INCB 018424
Chemical Name:
βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
Molecular Weight:
306.37
Molecular Formula:
C17H18N6
Solubility:
Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).
Physical Properties:
White solid
Purity:
99% by HPLC
NMR (Conforms)
Storage Temperature:
-20°
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee

Ruxolitinib (941678-49-5) is a potent and selective JAK1/2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1  Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4 Clinically useful cancer chemotherapeutic.

References/Citations:

1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636
2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109
3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med. 23 1072
4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget 8 34687